AbCellera
Discovers and develops antibody therapeutics using high throughput microfluidics.
What they do
AbCellera partners with pharmaceutical companies to search and analyze natural immune systems for potential antibody therapies. Their technology combines microfluidics, genomics, and machine learning to rapidly identify drug candidates for diverse therapeutic areas.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Antibody discovery
- Product type
- Service
- Stage
- Public
- Headquarters
- Vancouver, Canada
- Region
- North America
- Founded
- 2012
- Total funding
- $245M raised
Notable investors: Viking Global Investors, Peter Thiel, OrbiMed, DCVC.